Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Newron Pharmaceuticals
Newron Pharmaceuticals is developing novel therapies for diseases of the central nervous system and pain.
Sector
Subsector
Location
total rounds
total raised
Ascent Therapeutics
Ascent Therapeutics develops pepducins, a new class of drugs targeting G-protein coupled receptors.
Sector
Subsector
Location
total rounds
total raised
Lewis and Clark Pharmaceuticals
Lewis and Clark Pharmaceuticals develops potent treatments for cancer and inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Zogenix
Zogenix develops and commercializes differentiated CNS and pain therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 18.01.2024. Their latest round Post-IPO Equity
Oberland Capital
Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors7
Number of lead investors
Number of investors
Oberland Capital
Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Aisling Capital
Aisling Capital is a venture capital firm based in New York that focuses on investing in the pharmaceutical and biotechnology sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Dov Goldstein
Dov joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the company’s growth strategies as well as operational finance and business development. Previously, Dov was CEO at RIGImmune from 2018 to 2020, CFO of Schrödinger from 2017 to 2018, and a partner at Aisling Capital from 2006 to 2017. From 2014 to 2015, he served as the CFO of Loxo Oncology, which was later acquired by Lilly for $8 billion. From 2000 to 2005, Dov served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for $1.9 billion), where he raised over $250 million in equity financing and played major roles in the company’s partnership transactions. Dov currently serves on the board of directors of Gain Therapeutics, Neubase Therapeutics, and Coya Therapeutics, and previously held seats on the boards of, ADMA Biologics, Cempra Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, and Loxo Oncology. Dov has an MD from Yale School of Medicine, an MBA from Columbia Business School, and a BS in Biological Sciences from Stanford University.
current job
Domain Associates
Domain Associates is a venture capital firm that invests exclusively in life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Nicole Vitullo
Nicole Vitullo joined Domain Associates, L.L.C. in 1999 and became a Partner in 2004. She has full management responsibility for Domain Public Equity Partners, L.P. and is also involved in distribution/liquidation strategies for the public companies in Domain Associate’s venture capital portfolios. Present board memberships include Celator Pharmaceuticals, Inc.; Cerexa, Inc.; Ruxton Pharmaceuticals; and Marinus Pharmaceuticals. Past Board memberships include Onyx Pharmaceuticals and Eunoe, Inc. From 1992-1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. From 1991-1992, Ms. Vitullo served as the Director of Corporation Communications and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Ms. Vitullo spent 12 years at Eastman Kodak, most recently in Corporation Development where she was involved in the development management of Kodak’s venture capital activities. Ms. Vitullo has a B.A. and an M.B.A. from the University of Rochester.
current job
People
Founders1
Roger S. Newton
Roger Newton is the Sr. VP and Director at Esperion Therapeutics.
current job
Roger S. Newton
Employee Profiles57
Brittany Baratz
Senior travel and expense specialist
Laurie Danison
Senior manager, collaboration and web services
Hemant Mistry
Executive director, head of program management
Benjamin Church
Head of corporate communications and investor relations
Christian Schell
Manager, cgmp quality systems - drug product
Activity
Recent News3
The graph reveals the ratio (%) of positive news articles in a chosen time range